Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

1. Hengrui Pharma's drug shows positive obesity treatment data in late-stage trial. 2. HRS9531 achieved nearly 18% weight loss, competing against Eli Lilly's Zepbound. 3. Approval in China is imminent, but U.S. market entry may take years. 4. Zepbound assists up to 21% weight loss, complicating competitive landscape. 5. Hengrui's drug has gastrointestinal side effects similar to other GLP-1 treatments.